19. Mehra M, Desai S, Ruschitzka F, Patel A. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID – 19: a multinational registry analysis. Lancet 2020 electronic publication. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180- 6/fulltext 20. World Health Organization News. WHO discontinues hydroxychloroquine and lopinavir / ritonavir treatment arms for COVID – 19. https://www.who.int/news/item/04-07-2020-who-discontinues- hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 21. Mehra M, Desai S, Kuy S, Henry T, Patel A. Cardiovascular disease, drug therapy, and mortality in COVID – 19. New England Journal of Medicine 2020 electronic publication. https://www.nejm.org/doi/full/10.1056/NEJMe2020822 22. Office of the Commissioner. Coronaviris (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine | FDA 23. Borba M, Val F, Sampiano V, et al. Effect of high vs low dose of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. Journal of the American Medical Association Open 2020. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499 24. Axfors C, Schmitt A, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta – analysis of randomized trials. Nature Communications 2021; 12: 2349 – 2361 https://www.nature.com/articles/s41467-021-22446-z
Anchorlines, June/July 2022
11
Made with FlippingBook - professional solution for displaying marketing and sales documents online